Objective: Reactive oxygen species (ROS) have been implicated in the progression of ventricular hypertrophy to congestive heart failure. However, the source of increased oxidative stress in cardiomyocytes remains unclear. Methods: Here we examined NADPH oxidase and mitochondria as sources of ventricular ROS production in a rat model of right-ventricular (RV) failure (CHF) induced by pulmonary arterial hypertension (PAH). Results: Western analysis showed increased expression of the catalytic subunit gp91 phox of NADPH oxidase as well as its activator Rac1 in RV in CHF compared to non-failing myocardium (CON). In addition, analysis of mitochondrial respiratory chain complexes showed a selective increase in the expression of Complex II subunit B. Using lucigenin chemiluminescence, tissue homogenates showed increased NADPH oxidase and Complex II-dependent ROS production in failing RV, with no increase in the left ventricle. Functional analyses of isolated RV mitochondria showed an increase in Complex II activity as well as Complex II-associated ROS production in CHF vs CON. An increase in the reduction state of the mitochondrial Coenzyme Q in failing RV, together with increased expression of hypoxia-inducible factor 1α, indicated conditions in CHF that strongly favor ROS production by mitochondria. Reduced ROS-scavenging capacity was indicated by decreased mRNA levels of superoxide dismutases. Oxidative stress in failing RV was indicated by a two-fold increase in the level of phospho-p38 mitogen-activated protein kinase and by immunohistochemical evidence of extensive protein nitration. Conclusions: These data show that the development of PAH-induced RV heart failure is associated with an increased capacity for ROS production by NADPH oxidase as well as mitochondria. The selective increase in expression and activity of mitochondrial Complex II may be particularly important for ventricular ROS production in heart failure.
Introduction
Reactive oxygen species (ROS) such as superoxide (O 2 − ) have been shown to be harmful to proteins, lipids and DNA. An increase in cellular ROS levels leads to oxidative stress [1] and this has been implicated in the etiology of a wide variety of diseases, including cystic fibrosis, cancer, type-2 diabetes, Alzheimer's disease, Parkinson's disease, arteriosclerosis, as well as in myocardial ischemia/reperfusion injury [2] . Recently, increased ROS production was also suggested to play a role in the progression of both left (LV) and right ventricular (RV) hypertrophy to congestive heart failure [3] [4] [5] . This is supported by several animal studies showing prevention of heart failure by antioxidant treatment [6] [7] [8] . However, the source of the ROS production is a matter of intense debate, as recently reviewed by Murdoch et al. [9] . Studies of LV hypertrophy and failure using different animal models as well as human material indicate either membrane-bound NADPH oxidase [3, 10] or mitochondria as the principal source of increased ROS production [11] [12] [13] . Additionally, xanthine oxidase and uncoupled endothelial nitric oxide synthase have also been implicated [9, 14] . In the case of mitochondrial ROS production, there are several potential sources within the mitochondrial electron transport chain, i.e., Complex I, II and III. Of these complexes the contribution to ROS production by Complex III is best understood. Complex III contributes to ROS generation by auto-oxidation of the ubisemiquinone anion radical (UQ − ). During this process, oneelectron reduction of oxygen by UQ − leads under certain conditions to O 2 − production [15] . The site of Complex I O 2 − generation is less precisely known. It was suggested that O 2 − is generated either by reverse electron transfer upon succinate oxidation at Complex II, or in much lower amounts by forward electron transfer from NAD + -linked substrates [2] . Several authors have considered succinate dehydrogenase (Complex II) as a source of ROS, although not in the context of heart failure [16] . Complex II consists of two subunits embedded in the inner membrane of the matrix surface and stabilized by anchoring proteins. Complex II readily generates O 2 − when solubilized, most probably by oxidation of the flavin semiquinone radical formed by reduced flavin in the absence of an immediate electron transfer partner [16] . This can happen in vivo when the enzyme is damaged by oxidative stress or aging [2] or under hypoxic conditions [17] .
Studies of RV remodeling and failure so far point to a role of diminished cellular antioxidant activity, but ROSproducing activities have not yet been determined [4, 5] . In the present study, we used an established model of RV failure following pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT) [18] . MCT is a pyrrolizidine alkaloid, which is oxidized to monocrotaline pyrolle in the liver and this bioactive metabolite, which has a short half-life, selectively injures the vascular endothelium of the lung, leading to pulmonary hypertension [19] .
We show that both NADPH oxidase and mitochondriaderived ROS production increases in RV failure. Unexpectedly, mitochondria from failing hearts were characterized by increased expression and activity of Complex II. Additional experiments suggest that this complex may play an important role in right-ventricular ROS production in heart failure.
Materials and methods

Animals
Animals were treated according to the national guidelines and with the permission of the Institutional Animal Care and Use Committee (IACUC) of the VU University Medical Center Amsterdam, The Netherlands; which conforms with the Guide for the Care Animals were randomly assigned to two groups and received a single subcutaneous injection with either saline (control group (CON)), or 80 mg MCT/kg body weight (congestive heart failure group (CHF)). The animals were killed 25 days later with an isoflurane overdose, and heart and lungs were excised. Hearts were rinsed by perfusion and RV and LV weights were determined. Tissue samples were snapfrozen in liquid nitrogen and stored at − 80°C.
Force measurements
A parallel group of CON and CHF animals was used for assessing RV contractile properties by analysis of isolated trabeculae at 25 days after imposition of pressure overload. The heart was rapidly excised and a trabecula was isolated from the RV as described in detail before [20] . Trabeculae were stretched to 87% of the length at which maximum force was developed (L max ), yielding a passive force of ∼ 8% of F max . Trabeculae were equilibrated in Tyrode buffer (120 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4 , 1 mM CaCl 2 , 2 mM NaH 2 PO 4 , 24 mM NaHCO 3 , 10 mM Glucose, pH 7.4), 95% O 2 , 5% CO 2 , 24°C for 45 min at a stimulation frequency of 0.5 Hz. Maximum force was determined by post-extrasystolic potentiation (PESP) following stimulation at 6 Hz at 37°C. The force-frequency relationship (FFR) was determined at 37°C by measuring the developed active force relative to baseline (0.2 Hz) in response to a stepwise increase in the stimulation frequency up to 8 Hz. Length and dry-weight of the trabeculae were determined to calculate the cross-sectional area, assuming a cylindrical preparation.
Isolation of mitochondria and oxygen consumption
Mitochondria were isolated, essentially as described previously [21] , in medium containing 225 mmol/L Mannitol, 10 mmol/L MOPS, 75 mmol/L sucrose, 1 mmol/L EDTA, 0.5% BSA and 12 mg protease (Bacterial proteinase, Fluka), pH 7.25. Protein content was determined using a BCA kit (Amersham), with BSA as the standard.
The respiration was measured at 25°C with a Clark type oxygen electrode in a micro-chamber equipped with a magnetic stirring device in medium containing 225 mmol/L Mannitol, 75 mmol/L sucrose, 5 mmol/L MOPS, 3 mmol/L KH 2 PO 4 , 7 mmol/L K 2 HPO 4 , 1 mmol/L EDTA, pH: 7.1) (final volume 2 ml). The intactness of mitochondria was confirmed by measuring the respiratory control ratio, i.e., the respiration rate in state 3 (in the presence of 0.5 mmol/L ADP) over the respiration rate in state 4 (non-phosphorylating respiration) using succinate (10 mmol/L) as the respiratory substrate and in the presence of rotenone (5 μmol/L). The respiratory control ratios were: CON: 2,08 ± 0,20 (n =5); CHF: 2,09 ±0,21 (n =6), means ± SD. The measurements with isolated mitochondria were performed in modified HEPES buffer in the presence of rotenone (1 μmol/L) and (10 mmol/L) succinate [22] as substrate, with or without TTFA (1 μmol/L) or Myxothiazol (Myxo) (1 μmol/L).
Lucigenin chemiluminescence
Protein extraction, immunoblotting and immunofluorescence microscopy
RV tissue homogenates were immunoblotted for Oxidative Phosphorylation (OXPHOS) complexes using a kit containing a set of premixed monoclonal antibodies against an essential single subunit from each of the 5 OXPHOS complexes from human mitochondria (Mitosciences); ND6 (Complex I), SDHB (Complex II), core protein 2 (Complex III), COX II (Complex IV) (not cross reactive with rat tissue), F1α ATP synthase (Complex V). The same RV tissue homogenates were also immunoblotted for gp91 phox (Santa Cruz), Rac1 (Chemicon), p-p38 (Santa Cruz) and HIF-1α (Santa Cruz). Western-blotting reagents were purchased from Amersham International (Amersham, UK). Equal amounts of protein (10 μg) were separated by electrophoresis (10 or 20% SDS-PAGE) and transferred to nitrocellulose membranes. Equal protein transfer was checked by Ponceau staining and samples were normalized using α-actin staining (Sigma). Membranes were blocked with 5% non-fat milk (Bio-Rad) in 20 mmol/L Tris-HCl buffered saline (TBS)/Tween, pH: 7.6; for 1 h at room temperature. The antibodies were incubated overnight at 4°C in TBS containing 1% non-fat milk. After membranes were washed with TBS/ Tween 20, they were incubated with the appropriate secondary antibodies conjugated to horseradish peroxidase for 1 h at room temperature. Bands were visualized by enhanced chemiluminescence and quantified using a FujiFilm LAS 3000 laser densitometer.
To assess myocardial nitrotyrosine content, RV cryo sections were incubated with a primary antibody (rabbit) raised against nitrotyrosine (Molecular Probes), then incubated with the appropriate secondary antibody and visualized by immunofluorescence microscopy, as previously described by Bouwman et al. [23] .
Cytochrome-a amount
Spectral scans were between 500 and 650 nm, with 578 nm as reference, 3 nm bandwidth and a scanning rate of 5 nm s − 1 . To determine the total amount of the cytochrome-a, spectra were recorded with mitochondria diluted (40×) in 5 mM MOPS pH 7.2 in the absence of substrate (oxidized) and after addition sodium dithionite (reduced). A difference spectrum was calculated by subtraction of the oxidized from the reduced spectrum. For cytochrome-a, the difference spectrum was corrected for light scattering by subtracting a straight line between 580 and 650 nm. The spectrum was deconvoluted for one Gaussian peak (603.7 nm peak, 19.4 nm width) [24] . The area of the peak was taken to be proportional to the amount of cytochrome-a and divided by the amount of protein in the cuvet.
Real-time quantitative RT-PCR analysis
Gene-specific primers (Invitrogen) were designed as previously described (Table 1) [18] . Hypoxanthine-guanine phosporibosyltransferase (HPRT) was used as an internal control to normalize gene expression. A total of 5 μg total RNA were used to generate cDNA strands in a 20 μl reaction volume, using the Cloned AMV First Strand Synthesis Kit (Invitrogen). An equivalent of 25 ng of total RNA was subsequently used in the amplification with 50 nM gene-specific primers and 4 μl of CYBR green master mix (Applied Biosystems) in a total volume of 8 μl, using standard cycle parameters on an Applied Biosystems model 7700.
Coenzyme Q reduction
As previously described by Wagner et al. [25] , freshly isolated mitochondria (0.2-0.7 mg protein) from control and Table 1 Primers used in the real-time PCR determination of the expression levels of superoxide dismutases 1 and 2
Gene
GenBank accession number Forward primer (5′-3′) Reverse primer (5′-3′) Amplicon length
failing myocardium were added to 1 ml of reaction medium. The mixture was then added to 3 ml 0.2 M HClO 4 in methanol (0°C). Rapidly, 3 ml ice cold petroleumether (boiling point 40-60°C) was added and the mixture was vortexed for 30 s. After the mixture was centrifuged (1000 ×g, 1 min) the upper phase was removed and transferred to a test tube and another 3 ml of ice-cold petroleumether was added to the lower phase and the mixture was again vortexed and centrifuged. The upper phases were combined and evaporated to dryness under a flow of nitrogen.
After evaporation the extracted ubiquinone/ubiquinol was resuspended in 60 μl ethanol with a glass rod and analyzed by HPLC (Perkin Elmer LC-235 diode array with a Gilson pump model 303). The column was a Lichrosorb (Phenomenex) 10 RP 18 reversed phase (4.6 × 250 mm), with ethanol: methanol (3:2, v/v) as the mobile phase at a flow rate of 1 ml/ min. Detection of the quinones was performed at 290 nm. The amounts of UQ10 and UQ10-H2 were calculated from the peak areas. Calibration of the peaks was performed using oxidized and reduced UQ10 (Sigma).
Statistical analysis
The results are presented as Mean ± SEM. Data were analyzed using a t-test, p b 0.05 was considered significant.
Results
Monocrotaline-induced right-ventricular failure
As reported previously [18, 26] a dose of 80 mg/kg body weight MCT resulted in an increase in pulmonary arterial hypertension and subsequent RV hypertrophy and failure. The degree of RV hypertrophy 25 days after MCT treatment is indicated by the RV/LV + Septum weight ratios depicted in Fig. 1A . Lung weight was determined as an indication of the degree of pulmonary arterial hypertension [18] , (Fig. 1B) . The MCT-dependent increase is not related to edema, since dry-to-wet weight ratios of lung tissue do not differ between the groups, as previously shown [18] . All CHF animals showed signs of heart failure, including pleural effusion and ascites. Contractile properties of RV trabeculae at day 25 were analyzed to assess myocyte function relative to controls. Control trabeculae exhibited a positive FFR between 0.2 and 8 Hz, in agreement with earlier reports [27, 28] , while those from the CHF group showed no potentiation, indicative of the critical impairment of myocyte function in heart failure ( Fig. 1C) .
Expression of NADPH oxidase subunits and mitochondrial respiratory chain complexes in failing right ventricles
Since NADPH oxidase is reported to be an important source of ROS production in LV failure, we investigated the expression levels of the catalytic subunit gp91 phox of NADPH oxidase and its activator Rac1 in RV homogenates. The data in Fig. 2A show that the expression of both proteins was significantly increased in CHF. Mitochondrial ROS production is also reported in heart failure [11, 12] , where it was associated with decreased mitochondrial activity and possibly altered protein expression. We therefore first determined mitochondrial protein levels by Western analysis of subunits of the oxidative phosphorylation complexes (OXPHOS), i.e., I, II, III and V. Since the antibody from the OXPHOS Western blotting kit for the Complex IV subunit was not cross reactive with rat tissue, we determined densitometric analysis of expression levels of these components. Expression levels of each component were normalized to its CON level and expressed as Mean ± SEM; CON and CHF: n =4, ⁎ : p b 0.05 vs CON. (C) Cytochrome-a content was determined spectophotometrically. There was no difference in cytochrome-a content between CON and CHF. Data are expressed as Mean ± SEM; CON: n = 6 and CHF: n = 3.
NADPH oxidase and Complex II-dependent ROS production in ventricular homogenates
Having shown that NADPH oxidase is present in right ventricles and is increased in CHF, we wanted to know whether this could be a source of increased ROS production. Although non-specific effects of MCT on the heart are not expected based on the available literature (see [18] and references therein), we included LV tissue in the subsequent analyses of the failing RV to exclude the possibility of such effects. Therefore right and left ventricles from control and failing hearts were isolated 25 days after MCT injection, homogenized and analyzed for ROS production using lucigenin-enhanced chemiluminescence with NADPH as substrate and diphenyleneiodonium (DPI) as an inhibitor of the NADPH oxidase. Fig. 3A shows that NADPH-dependent ROS production was significantly increased in CHF in RV homogenates, but not in the LV of the same hearts. The RV-restricted increase in ROS production could furthermore be inhibited by DPI.
Given the reported ROS-generating capabilities of Complex II in bovine heart [16] , we tested whether the increased expression of Complex II in failing myocardium could play a role in ROS production in addition to NADPH oxidase. RV and LV homogenates were analyzed for Complex II-dependent ROS production with succinate as substrate and in the presence rotenone (50 μmol/L). ROS production was significantly increased in CHF in RV only. This activity was Complex-II dependent since it could be inhibited by TTFA (Fig. 3B ), but this does not necessarily identify Complex II as the source of ROS (see below).
Complex II-dependent mitochondrial ROS production
Given the limitations of assessing mitochondrial activities in crude homogenates, we further examined the Complex IIdependent ROS production using isolated mitochondria.
To determine whether the increased Complex II expression was functional, we determined the maximal rate of O 2 consumption with succinate as substrate. This rate was indeed increased in CHF relative to CON, with no difference between mitochondria isolated from LV in both groups (Fig. 4A) .
Furthermore, as can be seen in Fig. 4B , in the presence of succinate, only the isolated mitochondria from the failing RV showed increased Complex II-dependent, i.e., TTFA inhibitable, ROS production. To further pinpoint the actual site of ROS release, we used the Complex III-specific inhibitor myxothiazol, which prevents the binding of coenzyme Q at the Q o -site of Complex III. The data in Fig. 4B show that myxothiazol almost completely blocked the Complex IIdependent ROS production. This indicates that Complex III is the primary site of ROS release with succinate as substrate under the present in vitro conditions.
Antioxidant capacity in failing right ventricles
Since we determined that both NADPH oxidase and mitochondrial ROS production were increased in CHF, we also wanted to know whether there were any changes in antioxidant capacity of the failing myocardium. We therefore analyzed the expression of the superoxide dismutase-1 (SOD-1) and superoxide dismutase-2 (SOD-2) gene by RT-PCR. SOD-1 is predominantly located in the cytosol while SOD-2 is located in the mitochondria. The expression of both SOD-1 and SOD-2 was decreased in CHF compared to CON (Fig. 4C ).
Expression of hypoxia-inducible factor 1α in right ventricles
Complex II has been shown to be a potential site of ROS production under hypoxic conditions [17] , which may be present in hypertrophic myocardium [29] . We investigated whether this applied to our model by immunoblotting RV and LV homogenates for hypoxia-inducible factor 1α (HIF-1α) expression. Right-ventricular HIF-1α expression was indeed significantly increased in CHF compared to CON (Fig. 5A) , suggesting conditions in these cardiomyocytes that would increase Complex II-dependent ROS production. Additionally, the data in Fig. 5B show that there is positive correlation between SDHB and HIF-1α expression.
Signs of oxidative stress in failing right ventricles
Hydrogen peroxide (H 2 O 2 ), which is formed via dismutation of O 2 − by SOD-2, is produced by mitochondria in an elevated reduction state [13, 30] . Therefore, as an indicator of mitochondrial function in vivo, we measured the reduction state of Coenzyme Q. As depicted in Fig. 6A , the reduction state was significantly increased in CHF, indicating a condition that may favor ROS production. Since oxidative stress has been shown to lead to activation of p38 Mitogen Activated Protein Kinase (p38 MAPK) [31, 32] , we determined phospho-p38 levels in RV homogenates. Fig. 6B shows that phospho-p38 expression was significantly increased in CHF compared to CON. To confirm the presence of oxidative stress in the failing myocardium we stained cryo-sections of right ventricles for nitrotyrosine, a marker of oxidative stress [33] . The nitrotyrosine staining was markedly increased in CHF compared to CON (Fig. 6C) , indicating increased damage to proteins as a result of oxidative stress. 
Discussion
In the present study we demonstrated in failing RV myocardium: (1) Increased expression of the NADPH-oxidase subunit gp91 phox and its activator Rac1, and concomitantly increased ROS production in tissue homogenates. (2) The mitochondrial protein composition was characterized by a selectively increased expression of Complex II, which led to increased ROS production in tissue homogenates in the presence of succinate. (3) Isolated mitochondria showed increased Complex II activity and increased Coenzyme Q reduction levels. Complex III was the site of succinatedependent ROS production. (4) Ventricular hypoxia was indicated by increased HIF-1α expression. (5) Expression levels of SOD-1 and SOD-2 mRNA were reduced and nitrotyrosine staining confirmed oxidative stress.
Collectively, these findings indicate that PAH-induced ventricular failure is associated with increased myocardial oxidative stress, at least in part caused by both a cytosolic and a mitochondrial component. The latter may be of particular importance, given the increased mitochondrial Coenzyme Q reduction levels and the apparent hypoxic condition of the failing ventricle.
NADPH oxidase-derived ROS production
As previously reported for LV hypertrophy and heart failure in both human and animal studies [9] , we also observed NADPH oxidase as a source of ROS production in the RV homogenates. NADPH oxidase consists of a catalytic unit called gp91 phox and regulatory subunits p47 phox , p67 phox , p40 phox [9] . The catalytic unit gp91 phox is furthermore activated by the small GTP-binding protein Rac1 [34] . In the present study, both pg91 phox and Rac1 expression increased in CHF ( Fig. 2A) . This is in line with the established role of gp91 phox and Rac1 in the activation of NADPH-oxidase activity in murine cardiac hypertrophy [3, 35] , as well as with a study in human LV myocardium from patients with either ischemic or dilated cardiomyopathy in which increased ROS production by NADPH oxidase was associated with increased expression of Rac1 [36] .
Mitochondria-derived ROS production
In contrast to studies of homogenates of failing LV from human and guinea pig showing NADPH oxidase as the principal source of ROS production [3, 10] , our data indicated mitochondria to be an additional source in RV homogenates in failure.
Expression levels in these RV homogenates of several components of the respiratory chain, i.e., Complex I, III, IV and V, as well as total ubiquinone/ubiquinol levels (Coenzyme Q), remained unchanged. The fact that these components do not change does not necessarily mean that other portions of these complexes remain the same. However, at least with respect to Complex I no alterations are apparent, since respiratory rates and mitochondrial ROS production with glutamate/malate as substrates were unchanged (data not shown). Unlike these complexes, the expression of the succinate dehydrogenase subunit B (SDHB) of Complex II was increased by 60% (Fig. 2B) . Maximal succinatedependent respiration of isolated mitochondria from failing RV was similarly increased (Fig. 4A) , indicating upregulation of the entire Complex II. In line with this, we found that isolated mitochondria from failing RV, but not from the LV, had significantly increased succinate-dependent ROS production (Fig. 4B) . Earlier data have shown that mitochondria respiring on succinate produce ROS through leakage of electrons from Complex III [22] , although in vitro analysis indicated that Complex II itself can be a site of ROS production under certain conditions [16] . However, our data showing almost complete inhibition of succinate-dependent ROS production by myxothiazol (Fig. 4B) [15] . These experiments were conducted in the presence of rotenone and it cannot be excluded that reverse electron transfer to Complex I may contribute to succinatedependent O 2 − generation under different conditions. However, experiments in which the effect of rotenone was tested ruled out a substantial role of Complex I as a site of ROS release in either group (data not shown).
Cellular hypoxia, which leads to an elevated reduction state of components of the respiratory chain, has been shown to trigger an increase in mitochondrial ROS release at Complex III [37] [38] [39] . This in turn activates p38 MAPK which is required for the stabilization of HIF-1α as part of the cellular response to the diminished oxygen availability [40, 37] . That a condition of sustained hypoxia and elevated reduction state applies to the mitochondria in failing RV in vivo in our study, is suggested by the increase in the reduction state of Coenzyme Q of freshly isolated RV mitochondria relative to that of mitochondria from the LVof the same hearts (Fig. 6A) , and by the significantly increased expression of HIF-1α in failing RV relative to the LV (Fig. 5A) . Furthermore, activation of p38 MAPK levels was similarly increased in the failing RV (Fig. 6B ) confirming our earlier observation [18] . The p38 MAPK is one of the effectors of the MAPK stress-signalling pathways and accumulating evidence also implicates p38 as a pro-apoptotic factor in ventricular remodeling and heart failure [41] . Activation of apoptosis has indeed been shown in PAH-induced RV failure [18, 42] .
Myocardial hypoxia in hypertrophy has been hypothesized to occur as a consequence of the mismatch between the increased oxygen demand of the hypertrophied cardiomyocytes and the limited capacity of the vasculature. Indeed, capillary density did not increase in proportion to myocyte growth in a study of MCT-induced RV hypertrophy and HIF-1α was detected in these myocytes [29] . HIF-1α is a member of the basic helix-loop-helix (bHLH) superfamily of eukaryotic nuclear transcription factors. The target genes regulated by HIF-1α include genes involved in angiogenesis, apoptosis and energy metabolism [43] . The latter group comprises key enzymes of glucose transport and glycolysis, whose expression is increased in chronic hypoxia as part of the switch from fatty acids to glucose as substrate, requiring less oxygen per mol of ATP produced. Complex II is in its entirety encoded by nuclear genes and our data showing a significant correlation between the protein levels of HIF1α and SDHB in the failing RV (Fig. 5B) , suggest a mechanistic link. However, to our knowledge transcriptional regulation of SDHB by HIF-1α has not been shown. Alternatively, the hypoxic condition indicated by increased HIF-1α expression will be associated with activation of AMP-Kinase [44] and subsequent activation of nuclear respiratory factor 1 (NRF-1) [45] . NRF-1 is one of the known transcription factors regulating SDHB [46] and its activation in hypoxia may explain the observed correlation between the expression of HIF-1α and SDHB.
Although our in vitro data and the studies cited above indicate Complex III as the main site of ROS release, other studies of Complex II in mitochondria from yeast and various tissues suggest that this complex is also a potential site of ROS production [16, [47] [48] [49] . Recent results using intact tissue show that such Complex II-derived ROS production is particularly high under conditions of hypoxia and elevated reduction state when Complex II may act as fumarate reductase rather than as SDH [17] . It can therefore not be ruled out that in the failing right ventricles Complex II is an additional site of ROS production in vivo.
Effects of oxidative stress in failing myocardium
Earlier studies of MCT-induced RV hypertrophy suggested a role of ROS in the progression to failure, based on a diminished antioxidant capacity and increased lipid peroxidation [4, 5, 50] . The former is in line with our data showing that both SOD-1 and SOD-2 mRNA expression is decreased in CHF compared to CON. Our data now suggest that rightventricular ROS production in fact increases in CHF. In combination with the apparent decrease in oxidant defense capacity, this may be expected to result in substantial oxidative stress in the hypertrophic cardiomyocyte in CHF. Increased levels of superoxide give rise to highly reactive peroxynitrite as a product of the reaction with nitric oxide. Peroxynitrite can react with and damage DNA, lipids and proteins, which can impair myocyte function [51] The data in Fig. 6C , showing increased protein tyrosine nitration in failing RV, indeed suggest the presence of substantial oxidative stress in the failing myocardium.
In summary, our data show increased expression of the catalytic subunit gp91 phox and its activator Rac1 of the myocardial NADPH oxidase in PAH-induced RV failure, together with a selective increase in mitochondrial Complex II expression. Although we show that this results in an increased capacity for mitochondrial and NADPH oxidase-derived ROS production, this study is limited by the fact that we did not assess ROS production under physiologically more relevant conditions. However, oxidative stress is evident in the failing RV and the apparent hypoxia and increased mitochondrial reduction state, which strongly favor ROS production, suggest that mitochondria are the principal source of ROS. Apart from the suggested role of ROS in inducing apoptosis, we think that mitochondrial ROS production may be particularly important in directly affecting contraction and Ca 2+ handling in heart failure, given that mitochondria are located in close proximity to the contractile apparatus and sarcoplasmic reticulum throughout the cardiomyocyte.
